Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Howmet Aerospace Inc (HWM) Price & Performance

ADMA Biologics IncTrade
Howmet Aerospace IncTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Howmet Aerospace Inc — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while Howmet Aerospace Inc trades at $283 (market cap $112.20B). The key difference: Howmet Aerospace Inc is far larger — about 50.5× ADMA Biologics Inc's market cap, and Howmet Aerospace Inc pays a 0.2% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMAHWM
Market Cap
$2.22B$112.20B
Sector
HealthIndustrials
52-Week High
$20.38$291.28
52-Week Low
$7.60$171.00
Enterprise Value
$2.29B$116.30B
Dividend Yield
0.2%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.

The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.

Howmet Aerospace Inc

Howmet Aerospace (HWM) trades at $283.80, up 0.03% today, with a bullish technical signal and strong support at $279. The company reported Q2 2026 EPS of $1.33, beating estimates, and raised full-year guidance due to robust aerospace and defense demand. Revenue grew 24% year-over-year, with a net income margin of 20.52% and ROE of 34.89%.

Outlook is positive with 84% analyst buy ratings and a $334.63 consensus price target, implying 18% upside. Risks include high valuation multiples (P/E 60.63) and capital expenditure increases. Earnings momentum and institutional confidence support further growth, but investors should monitor execution on expanded capacity plans.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Howmet Aerospace Inc

Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.

Read more on HWM